Cargando…

Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level

OBJECTIVE: This study aimed to analyze the clinical efficacy of dapagliflozin in the treatment of diabetic kidney disease and its impact on proteinuria levels in patients. METHODS: Retrospective analysis of medical records of 176 patients with diabetic kidney disease treated at our hospital from Jan...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ze-Jun, Wang, Gen-Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370422/
https://www.ncbi.nlm.nih.gov/pubmed/37502285
http://dx.doi.org/10.2147/DMSO.S421579
_version_ 1785077930343268352
author Jin, Ze-Jun
Wang, Gen-Zhen
author_facet Jin, Ze-Jun
Wang, Gen-Zhen
author_sort Jin, Ze-Jun
collection PubMed
description OBJECTIVE: This study aimed to analyze the clinical efficacy of dapagliflozin in the treatment of diabetic kidney disease and its impact on proteinuria levels in patients. METHODS: Retrospective analysis of medical records of 176 patients with diabetic kidney disease treated at our hospital from January 2020 to January 2022. According to the different treatment methods, the patients were divided into a control group (n=88) receiving enalapril maleate treatment and an observation group (n=88) receiving dapagliflozin treatment. The clinical treatment effects, blood glucose levels, renal function indicators, inflammation factor indicators, and adverse reactions were compared between the two groups. RESULTS: The total effective rate of treatment (97.73%) in the observation group was significantly higher than that (79.55%) in the control group (P<0.05). After treatment, the FPG, 2hPG, and HbAlc levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the Scr, BUN, UmAlb, UAER, UACR, and 24-hour urine protein quantitative levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the hs-CRP, IL-1β, and TNF-α levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group significantly lower than the control group (P<0.05). CONCLUSION: Compared with enalapril maleate alone, the combined application of dapagliflozin in the treatment of diabetic kidney disease has more significant clinical efficacy. It can further control patients’ blood sugar, reduce their body’s inflammatory response, alleviate or eliminate their proteinuria symptoms, promote the recovery of their renal function, and enhance the safety of their treatment to a certain extent, which helps to further improve the clinical treatment effect of patients.
format Online
Article
Text
id pubmed-10370422
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103704222023-07-27 Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level Jin, Ze-Jun Wang, Gen-Zhen Diabetes Metab Syndr Obes Original Research OBJECTIVE: This study aimed to analyze the clinical efficacy of dapagliflozin in the treatment of diabetic kidney disease and its impact on proteinuria levels in patients. METHODS: Retrospective analysis of medical records of 176 patients with diabetic kidney disease treated at our hospital from January 2020 to January 2022. According to the different treatment methods, the patients were divided into a control group (n=88) receiving enalapril maleate treatment and an observation group (n=88) receiving dapagliflozin treatment. The clinical treatment effects, blood glucose levels, renal function indicators, inflammation factor indicators, and adverse reactions were compared between the two groups. RESULTS: The total effective rate of treatment (97.73%) in the observation group was significantly higher than that (79.55%) in the control group (P<0.05). After treatment, the FPG, 2hPG, and HbAlc levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the Scr, BUN, UmAlb, UAER, UACR, and 24-hour urine protein quantitative levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the hs-CRP, IL-1β, and TNF-α levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group significantly lower than the control group (P<0.05). CONCLUSION: Compared with enalapril maleate alone, the combined application of dapagliflozin in the treatment of diabetic kidney disease has more significant clinical efficacy. It can further control patients’ blood sugar, reduce their body’s inflammatory response, alleviate or eliminate their proteinuria symptoms, promote the recovery of their renal function, and enhance the safety of their treatment to a certain extent, which helps to further improve the clinical treatment effect of patients. Dove 2023-07-22 /pmc/articles/PMC10370422/ /pubmed/37502285 http://dx.doi.org/10.2147/DMSO.S421579 Text en © 2023 Jin and Wang. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Jin, Ze-Jun
Wang, Gen-Zhen
Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
title Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
title_full Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
title_fullStr Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
title_full_unstemmed Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
title_short Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
title_sort clinical efficacy of dapagliflozin in the treatment of patients with diabetic nephropathy and its effect on proteinuria level
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370422/
https://www.ncbi.nlm.nih.gov/pubmed/37502285
http://dx.doi.org/10.2147/DMSO.S421579
work_keys_str_mv AT jinzejun clinicalefficacyofdapagliflozininthetreatmentofpatientswithdiabeticnephropathyanditseffectonproteinurialevel
AT wanggenzhen clinicalefficacyofdapagliflozininthetreatmentofpatientswithdiabeticnephropathyanditseffectonproteinurialevel